Origenis GmbH collaborates with US cancer center

Origenis introduces an AI Discovery Platform to identify and optimize small molecule preclinical development candidates for Glioblastoma


Origenis GmbH, a privately-held biopharmaceutical company based in Martinsried, announced on June 4, 2019 its collaboration with Memorial Sloan Kettering Cancer Center (MSK), New York, targeting glioblastoma (GBM), a rare but fatal brain cancer. GBM is one of the most fatal cancers due to the difficulty of achieving drug delivery through the blood brain barrier. Under the research and collaboration agreement, Origenis will use its proprietary AI platform for drug discovery and development.

“We welcome this opportunity to collaborate with Memorial Sloan Kettering, one of the world’s leading cancer research ­centers, to use our proven platform for discovering and synthesizing novel small molecules that can cross the blood brain barrier,” said Michael Almstetter, Chief Executive Officer at Origenis.  “We look forward to combining their cancer expertise with our unique approach to creating better preclinical development candidates more directly and quickly.”